Autopsy report · NCT03145831

A Long-Term Safety Study of Somavaratan in Japanese Children With Growth Hormone Deficiency

Cause of deathFutility Automatic label, confidence 0.9, unverified. How labels are made.

“The primary endpoint of non-inferiority to daily therapy in the pediatric Phase 3 study was not achieved”

The sponsor’s own words in the registry.

Life of this trial

Ran for about 8 months before it stopped.
21 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 3
Sponsor: Versartis Inc.
Sponsor type: Industry
Conditions: Growth Hormone Deficiency
Interventions: Somavaratan
Participants: 21
Sites: 1
Countries: United States

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.